Pharmacological Characterization of the Novel CRF1 Receptor Antagonist, Thiazolo[4,5-d] Pyrimidine Analog, M43
Biomolecules · 2025
DOI: 10.3390/biom15091265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Spyridon Marios Giatro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of West Attica, 12210 Egaleo, Greece. Hauptthemen laut MEDLINE: Receptors, Corticotropin-Releasing Hormone, Pyrimidines, Thiazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H.F.R.I, SARF, Hellenic Foundation for Research and Innovation.
Abstract (Originalsprache)
The corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1R) play a key role in the regulation of the hypothalamic–pituitary–adrenal (HPA) axis. Dysregulation of the HPA axis is associated with congenital adrenal hyperplasia (CAH) and depression. Non-peptide CRF1R-selective antagonists displayed antidepressant effects on animal models and are used for the management of CAH. To develop novel non-peptide CRF1R antagonists, we have previously designed and synthesized a series of substituted pyrimidines. Among these analogs, molecule 43 (M43) binds to CRF1R with the highest affinity. Based on this finding, we selected M43 for further pharmacological characterization in the present study. The results suggest that M43 is a potent CRF1R antagonist, blocking the ability of the CRF-related agonist, Tyr0-sauvagine, to stimulate (1) cAMP accumulation in HEK 293 cells expressing CRF1R and (2) the proliferation rate of RAW 264.7 macrophages. Computational studies suggest that the antagonist properties of M43 are mostly attributed to its ability to interact with residues in the allosteric pocket of CRF1R, comprised of the third, fifth, and sixth transmembrane domain residues, which block activation-associated structural rearrangements of the receptor. Our data will be used to design novel non-peptide CRF1R antagonists for clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of West Attica, 12210 Egaleo, Greece.
- Department of Pharmacology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
- Department of Clinical Chemistry, School of Medicine, University of Crete, 71003 Heraklion, Greece.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Alamein International University, Alamein 51718, Egypt.
- Department of Pharmaceutical Science, College of Pharmacy & Allied Health Professions, South Dakota State University, Brookings, SD 57007, USA.
ORCID-Profile: Spyridon Marios Giatro, Nastazia Lesgidou, Vlasios Karageorgos, Thomas Mavromoustakos, Maria Venihaki, Minos-Timotheos Matsoukas, George Liapakis
Förderung
- H.F.R.I
- SARF
- Hellenic Foundation for Research and Innovation
- Special Account for Research Funds of the University of Crete (SARF)
Zitieren
APA
Giatro, S. M., Komontachakis, G., Kalantidou, A., Lesgidou, N., Karageorgos, V., Teleb, M., Islam, M. R., Mavromoustakos, T., Fahmy, H., Venihaki, M., Matsoukas, M. T., & Liapakis, G. (2025). Pharmacological Characterization of the Novel CRF1 Receptor Antagonist, Thiazolo[4,5-d] Pyrimidine Analog, M43. Biomolecules. https://doi.org/10.3390/biom15091265
Vancouver
Giatro SM, Komontachakis G, Kalantidou A, Lesgidou N, Karageorgos V, Teleb M, et al. Pharmacological Characterization of the Novel CRF1 Receptor Antagonist, Thiazolo[4,5-d] Pyrimidine Analog, M43. Biomolecules. 2025. doi:10.3390/biom15091265
BibTeX
@article{Giatro2025,
author = {Giatro, Spyridon Marios and Komontachakis, George and Kalantidou, Aikaterini and Lesgidou, Nastazia and Karageorgos, Vlasios and Teleb, Mohamed and Islam, Md Rabiul and Mavromoustakos, Thomas and Fahmy, Hesham and Venihaki, Maria and Matsoukas, Minos-Timotheos and Liapakis, George},
title = {Pharmacological Characterization of the Novel CRF1 Receptor Antagonist, Thiazolo[4,5-d] Pyrimidine Analog, M43},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15091265}
}
EUVIMED